Medpace: third-quarter revenue growth picks up and 2026 guidance is raised
Medpace reported 8.5% revenue growth and 16% EBITDA growth for the third quarter, and lifted its full-year 2026 guidance across four key metrics.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, Medpace's revenue in the third quarter rose 8.5% year on year, while EBITDA climbed 16.0%. The company attributes the performance to higher new awards and a larger backlog.
Management also raised its 2026 full-year outlook for revenue, EBITDA, net income and earnings per share.
why it matters
For investors in the contract research sector, two factors matter: demand for clinical trials and the durability of the order backlog. Raising all four forward metrics at once signals management confidence in continued growth, though the report remains a company-level event of moderate scale for the broader market.
market impact
Medpace and CRO peers: strong quarter and higher guidance support interest in the stock
tags
instruments
sources
- MEDP: Q3 growth strengthened as awards rose and FY2026 guidance moved higher — TradingView, 22 October 2026 at 03:05 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗